GNPX 2018 Proxy Statement

23 own more than 4.99% of our outstanding common stock. The share ownership numbers and percentages for Sabby Volatility Warrant Master Fund, Ltd. in the table above reflect this 4.99% blocker. As of August 1, 2018, Sabby Volatility Warrant Master Fund, Ltd. holds a warrant to purchase 1,141,870 shares of our common stock and has the right to acquire from us 350,000 shares of our common stock. Sabby Management, LLC is the investment manager of Sabby Volatility Warrant Master Fund, Ltd. and shares voting and investment power with respect to these shares in this capacity. As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of Sabby Volatility Warrant Master Fund, Ltd. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein. The address of principal business office of Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC and Hal Mintz is 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458. Sabby Volatility Warrant Master Fund, Ltd. is not a registered broker-dealer or an affiliate of a registered broker-dealer. (6) Beneficial ownership includes shares of common stock issuable upon exercise of a warrant that are subject to a 9.99% ownership blocker, pursuant to which shares of our common stock may not be issued to the extent such issuance would cause Hudson Bay Master Fund, Ltd. to beneficially own more than 9.99% of our outstanding common stock. The share ownership numbers and percentages in the table above reflect this 9.99% blocker. As of August 1, 2018, Hudson Bay Master Fund, Ltd. holds a warrant to purchase 1,141,870 shares of our common stock. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Sander Gerber disclaims beneficial ownership over these securities. (7) Includes (a) 1,614,152 shares of common stock held by Laura Lane Biosciences, LLC and (b) 645,572 shares of common stock that Mr. Varner has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options. Mr. Varner holds voting power over the shares held by Laura Lane Biosciences, LLC. (8) Consists of 78,008 shares of common stock that Dr. Pham has the right to acquire from us within 60 days of Aguste 1, 2018 pursuant to the exercise of stock options. (9) Includes 492,521 shares of common stock that Mr. Confer has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options. (10) Consists of 307,111 shares of common stock that Mr. Friedman has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options. (11) Consists of 307,111 shares of common stock that Mr. Pearson has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options. EXECUTIVE OFFICER AND DIRECTOR COMPENSATION Our named executive officers for the year ended December 31, 2017, which consist of our principal executive officer and our two other most highly compensated executive officers, are: • J. Rodney Varner, our Chief Executive Officer; • Julien L. Pham, M.D., M.P.H., our President and Chief Operating Officer; and • Ryan M. Confer, our Chief Financial Officer.